Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538076 | 0.84 | NOTUM (0.63) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL4482463 | 0.81 | NOTUM (0.54) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL4564455 | 0.79 | NOTUM (0.58) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL30031457 | 0.79 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL26971182 | 0.79 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL17984483 | 0.78 | NOTUM (0.51) | NOTUMKEAP1 | |
| SCHEMBL5612825 | 0.76 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL22325390 | 0.76 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL16787394 | 0.76 | NOTUM (0.58) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL1059987 | 0.76 | MAPT (0.58) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | NOTUM 3443/4885KEAP1 3333/4885MIF 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.